Supreme Court Extends Abortion Pill Access Until Thursday

Women across America can continue accessing mifepristone through mail order and telemedicine appointments, thanks to a temporary Supreme Court order issued Monday. Justice Samuel Alito extended current access rules while the court deliberates on a Louisiana lawsuit challenging FDA regulations.

The case centers on mifepristone, an abortion medication approved by the FDA in 2000 and used in nearly two-thirds of all abortions in 2023. Louisiana filed suit claiming federal rules allowing mail delivery and telehealth prescriptions undermine state restrictions, despite FDA scientists repeatedly confirming the drug's safety over more than two decades.

A federal appeals court previously ruled to suspend mail access and telehealth visits, but the Supreme Court blocked those restrictions from taking effect. The temporary extension means women seeking medication abortions can still obtain prescriptions remotely and receive pills by mail without requiring in-person doctor visits.

This marks the second time in three years the Supreme Court has faced similar challenges to mifepristone access. In 2024, the court unanimously dismissed an earlier lawsuit brought by physicians who opposed abortion, ruling they lacked legal standing to sue.

Mainstream medical organizations, pharmaceutical companies, and drug manufacturers have urged the court to maintain current access. Industry groups warn that overturning FDA decisions on mifepristone could destabilize the entire drug approval process, potentially affecting medications far beyond reproductive health.

The Bright Side

The temporary extension protects established medical practice while the legal process unfolds. Major medical groups and pharmaceutical experts continue defending evidence-based FDA regulations that have governed safe medication access for over 25 years.

Mifepristone has been available in the United States for more than two decades with extensive safety data supporting its use. The FDA has gradually eased initial restrictions based on years of real-world evidence showing the medication works safely when prescribed through telemedicine and dispensed by mail.

The court's decision to maintain access during deliberations means women facing time-sensitive healthcare decisions can continue receiving care without sudden disruption. For now, established pathways remain open.